Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.
暂无分享,去创建一个
Jeremy J. W. Chen | Ker-Chau Li | Y. Lai | Yih-Leong Chang | J. Shih | Yi-Wei Chen | Shin-sheng Yuan | Hsuan-Yu Chen | Sung-Liang Yu | G. Chang | Chiou-Ling Cheng | Pan‐Chyr Yang | Tsung-Ying Yang | Kun-Chieh Chen | Chong-Jen Yu | K. Su | Chien-Yu Lin | Chin-Di Wang | Huei-Wen Chen | Chung-Ping Hsu | Yi-Chiung Hsu | Chia-Hsin Liu | Kuo-Hsuan Hsu | J. Hsia | Chu-Chun Hsu | Kangning Yang | T. Lin | Guani Wu | Chih‐Yi Chen | K. Li | K. Li | Ker-Chau Li
[1] J. Shih,et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. , 2011, American journal of respiratory and critical care medicine.
[2] M. Paquet,et al. Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. , 2011, Blood.
[3] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[4] A. Gemma,et al. F1000 highlights , 2010 .
[5] G. Gores,et al. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis , 2010, Oncogene.
[6] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[7] J. Abbruzzese,et al. F1000 highlights , 2009, JAMA.
[8] R. McLendon,et al. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. , 2009, Cancer research.
[9] C. Moskaluk,et al. Combined genomic and gene expression microarray profiling identifies ECOP as an upregulated gene in squamous cell carcinomas independent of DNA amplification , 2009, Oncogene.
[10] M. Meyerson,et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.
[11] Chris Sander,et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.
[12] E. C. Xu,et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. , 2008, Lung cancer.
[13] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[14] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[15] Yih-Leong Chang,et al. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response , 2008, Clinical Cancer Research.
[16] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[17] Jude Kendall,et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.
[18] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[19] H. Sasaki,et al. PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.
[20] M. Maemondo,et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Jänne,et al. Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2006, Clinical Cancer Research.
[22] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[23] Yih-Leong Chang,et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer , 2006, International journal of cancer.
[24] S. Ramalingam,et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Shih-Feng Tsai,et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.
[26] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[27] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[29] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[31] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[32] M. Kuwano,et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.
[33] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[34] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] C. James,et al. Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. , 2003, Cancer research.
[36] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[37] Christian Klämbt,et al. Epidermal growth factor receptor signaling , 2001, Current Biology.
[38] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[39] S. Manoir,et al. Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. , 1997, Cancer research.
[40] M. Esteller. Molecular Origins of Cancer Epigenetics in Cancer , 2022 .